Drug Discovery by Targeting Mutant KRAS

Author(s): Na Ye.

Journal Name: Current Topics in Medicinal Chemistry

Volume 19 , Issue 23 , 2019

Become EABM
Become Reviewer

[1]
Wu, H-Z.; Xiao, J-Q.; Xiao, S-S.; Cheng, Y. KRAS: A promising therapeutic target for cancer treatment. Curr. Top. Med. Chem., 2019, 19(23), 2081-2097.
[2]
Chen, F.; Alphonse, M.P.; Liu, Y. Liu, Q. Targeting mutant KRAS for anticancer therapy. Curr. Top. Med. Chem., 2019, 19(23), 2098-2113.
[3]
Ye, N.; Xu, Q.; Li, W.; Wang, P.; Zhou, J. Recent advances in developing k-ras plasma membrane localization inhibitors. Curr. Top. Med. Chem., 2019, 19(23), 2114-2127.
[4]
He, H.; Xu, C.; Cheng, Z.; Qian, X.; Zheng, L. Drug combinatorial therapies for the treatment of KRAS mutated lung cancers. Curr. Top. Med. Chem., 2019, 19(23), 2128-2142.
[5]
Shao, Y-T.; Ma, L.; Zhang, T-H.; Xu, T-R.; Ye, Y-C.; Liu, Y. The application of the RNA interference technologies for KRAS: current status, future perspective and associated challenges. Curr. Top. Med. Chem., 2019, 19(23), 2143-2157.
[6]
Hoo, W.P.Y.; Siak, P.Y.; In, L.L.A. Overview of current immunotherapies targeting mutated KRAS cancers. Curr. Top. Med. Chem., 2019, 19(23), 2158-2175.
[7]
Zhu, Z.; Xiao, S.; Hao, H.; Hou, Q.; Fu, X. Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations in the occurrence and treatment of pancreatic cancer. Curr. Top. Med. Chem., 2019, 19(23), 2176-2186.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 23
Year: 2019
Page: [2079 - 2080]
Pages: 2
DOI: 10.2174/156802661923191113144238

Article Metrics

PDF: 39
HTML: 3